Transfer learning between preclinical models and human tumors identifies a conserved NK cell activation signature in anti-CTLA-4 responsive tumors.


Journal

Genome medicine
ISSN: 1756-994X
Titre abrégé: Genome Med
Pays: England
ID NLM: 101475844

Informations de publication

Date de publication:
11 08 2021
Historique:
received: 08 03 2021
accepted: 27 07 2021
entrez: 11 8 2021
pubmed: 12 8 2021
medline: 17 2 2022
Statut: epublish

Résumé

Tumor response to therapy is affected by both the cell types and the cell states present in the tumor microenvironment. This is true for many cancer treatments, including immune checkpoint inhibitors (ICIs). While it is well-established that ICIs promote T cell activation, their broader impact on other intratumoral immune cells is unclear; this information is needed to identify new mechanisms of action and improve ICI efficacy. Many preclinical studies have begun using single-cell analysis to delineate therapeutic responses in individual immune cell types within tumors. One major limitation to this approach is that therapeutic mechanisms identified in preclinical models have failed to fully translate to human disease, restraining efforts to improve ICI efficacy in translational research. We previously developed a computational transfer learning approach called projectR to identify shared biology between independent high-throughput single-cell RNA-sequencing (scRNA-seq) datasets. In the present study, we test this algorithm's ability to identify conserved and clinically relevant transcriptional changes in complex tumor scRNA-seq data and expand its application to the comparison of scRNA-seq datasets with additional data types such as bulk RNA-seq and mass cytometry. We found a conserved signature of NK cell activation in anti-CTLA-4 responsive mouse and human tumors. In human metastatic melanoma, we found that the NK cell activation signature associates with longer overall survival and is predictive of anti-CTLA-4 (ipilimumab) response. Additional molecular approaches to confirm the computational findings demonstrated that human NK cells express CTLA-4 and bind anti-CTLA-4 antibodies independent of the antibody binding receptor (FcR) and that similar to T cells, CTLA-4 expression by NK cells is modified by cytokine-mediated and target cell-mediated NK cell activation. These data demonstrate a novel application of our transfer learning approach, which was able to identify cell state transitions conserved in preclinical models and human tumors. This approach can be adapted to explore many questions in cancer therapeutics, enhance translational research, and enable better understanding and treatment of disease.

Sections du résumé

BACKGROUND
Tumor response to therapy is affected by both the cell types and the cell states present in the tumor microenvironment. This is true for many cancer treatments, including immune checkpoint inhibitors (ICIs). While it is well-established that ICIs promote T cell activation, their broader impact on other intratumoral immune cells is unclear; this information is needed to identify new mechanisms of action and improve ICI efficacy. Many preclinical studies have begun using single-cell analysis to delineate therapeutic responses in individual immune cell types within tumors. One major limitation to this approach is that therapeutic mechanisms identified in preclinical models have failed to fully translate to human disease, restraining efforts to improve ICI efficacy in translational research.
METHOD
We previously developed a computational transfer learning approach called projectR to identify shared biology between independent high-throughput single-cell RNA-sequencing (scRNA-seq) datasets. In the present study, we test this algorithm's ability to identify conserved and clinically relevant transcriptional changes in complex tumor scRNA-seq data and expand its application to the comparison of scRNA-seq datasets with additional data types such as bulk RNA-seq and mass cytometry.
RESULTS
We found a conserved signature of NK cell activation in anti-CTLA-4 responsive mouse and human tumors. In human metastatic melanoma, we found that the NK cell activation signature associates with longer overall survival and is predictive of anti-CTLA-4 (ipilimumab) response. Additional molecular approaches to confirm the computational findings demonstrated that human NK cells express CTLA-4 and bind anti-CTLA-4 antibodies independent of the antibody binding receptor (FcR) and that similar to T cells, CTLA-4 expression by NK cells is modified by cytokine-mediated and target cell-mediated NK cell activation.
CONCLUSIONS
These data demonstrate a novel application of our transfer learning approach, which was able to identify cell state transitions conserved in preclinical models and human tumors. This approach can be adapted to explore many questions in cancer therapeutics, enhance translational research, and enable better understanding and treatment of disease.

Identifiants

pubmed: 34376232
doi: 10.1186/s13073-021-00944-5
pii: 10.1186/s13073-021-00944-5
pmc: PMC8356429
doi:

Substances chimiques

Biomarkers 0
CTLA-4 Antigen 0
CTLA4 protein, human 0
Immune Checkpoint Inhibitors 0
Ipilimumab 0

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

129

Subventions

Organisme : NCI NIH HHS
ID : U01 CA196390
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA006973
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA062924
Pays : United States
Organisme : NCI NIH HHS
ID : R50 CA243627
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA212007
Pays : United States
Organisme : NIH HHS
ID : F30 CA239441
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA253403
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA184926
Pays : United States
Organisme : NCI NIH HHS
ID : F31 CA250135
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA177669
Pays : United States
Organisme : NCI NIH HHS
ID : P01 CA247886
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA197296
Pays : United States
Organisme : NCI NIH HHS
ID : F30 CA239441
Pays : United States

Informations de copyright

© 2021. The Author(s).

Références

Eur J Immunol. 1998 Mar;28(3):780-6
pubmed: 9541571
N Engl J Med. 2010 Aug 19;363(8):711-23
pubmed: 20525992
Blood Adv. 2020 Apr 14;4(7):1388-1406
pubmed: 32271902
Blood. 2018 Jan 4;131(1):58-67
pubmed: 29118008
Oncoimmunology. 2018 Dec 25;8(3):1557030
pubmed: 30723590
Cell Res. 2018 Apr;28(4):416-432
pubmed: 29472691
J Immunother. 2012 Oct;35(8):629-40
pubmed: 22996369
J Clin Invest. 2018 Oct 1;128(10):4654-4668
pubmed: 30198904
J Immunol. 1999 May 15;162(10):5910-6
pubmed: 10229827
Bioinformatics. 2017 Jun 15;33(12):1892-1894
pubmed: 28174896
Cell. 2018 Nov 1;175(4):998-1013.e20
pubmed: 30388456
J Immunol. 2000 Nov 15;165(10):5530-6
pubmed: 11067906
Cancer Immunol Res. 2019 Feb;7(2):230-243
pubmed: 30563830
J Leukoc Biol. 2002 Aug;72(2):305-11
pubmed: 12149421
Front Immunol. 2020 Jan 09;10:3010
pubmed: 31998304
Cancer Immunol Res. 2019 Jul;7(7):1162-1174
pubmed: 31088844
Cell. 2018 Nov 1;175(4):1014-1030.e19
pubmed: 30343900
J Immunol. 1999 Jul 1;163(1):62-70
pubmed: 10384100
Hum Immunol. 2000 Aug;61(8):721-8
pubmed: 10980383
J Immunol. 1992 Aug 15;149(4):1115-23
pubmed: 1380031
Oncoimmunology. 2016 Dec 7;6(2):e1261242
pubmed: 28344869
Pancreatology. 2014 Jul-Aug;14(4):295-301
pubmed: 25062880
J Immunol. 2004 Mar 1;172(5):2731-8
pubmed: 14978070
Nat Methods. 2015 May;12(5):453-7
pubmed: 25822800
Nat Methods. 2013 Nov;10(11):1096-8
pubmed: 24056875
J Hematother Stem Cell Res. 2001 Aug;10(4):535-44
pubmed: 11522236
Front Immunol. 2017 Jan 18;7:694
pubmed: 28149296
J Exp Med. 2001 Sep 17;194(6):823-32
pubmed: 11560997
Nat Methods. 2017 Oct;14(10):979-982
pubmed: 28825705
Trends Immunol. 2008 Jun;29(6):272-9
pubmed: 18468488
Bioinformatics. 2020 Jun 1;36(11):3592-3593
pubmed: 32167521
Int J Cancer. 2005 Nov 20;117(4):538-50
pubmed: 15912538
Cancer Immunol Res. 2019 Aug;7(8):1371-1380
pubmed: 31239316
J Immunol. 2014 May 1;192(9):4184-91
pubmed: 24688023
Int J Mol Sci. 2017 Oct 12;18(10):
pubmed: 29023417
Nature. 1988 Jun 9;333(6173):568-70
pubmed: 2967436
Pancreas. 2015 Apr;44(3):386-93
pubmed: 25621568
Immunity. 1996 Oct;5(4):311-7
pubmed: 8885864
Oncotarget. 2016 Nov 8;7(45):73845-73864
pubmed: 27650546
Cell Syst. 2015 Dec 23;1(6):417-425
pubmed: 26771021
Cell Syst. 2019 May 22;8(5):395-411.e8
pubmed: 31121116
J Vis Exp. 2011 Feb 02;(48):
pubmed: 21339714
J Immunother Cancer. 2015 May 19;3:18
pubmed: 25992289
J Allergy Clin Immunol. 2021 Jan;147(1):349-360
pubmed: 32417134
Cell Mol Immunol. 2019 Mar;16(3):242-249
pubmed: 30796351
Br J Cancer. 2018 Jan;118(1):9-16
pubmed: 29319049
Biol Blood Marrow Transplant. 2012 Jan;18(1 Suppl):S2-7
pubmed: 22226108
Front Genet. 2019 Apr 05;10:317
pubmed: 31024627
Hum Immunol. 2010 Oct;71(10):934-41
pubmed: 20650297
Immunity. 2018 Apr 17;48(4):812-830.e14
pubmed: 29628290
Scand J Immunol. 2002 Jan;55(1):53-60
pubmed: 11841692
Cell. 2018 Apr 5;173(2):400-416.e11
pubmed: 29625055
J Exp Med. 2000 Apr 17;191(8):1259-62
pubmed: 10770793
J Exp Med. 1996 Jun 1;183(6):2533-40
pubmed: 8676074
BMJ. 2007 Jan 27;334(7586):197
pubmed: 17175568
Am J Surg. 1989 Oct;158(4):361-6
pubmed: 2802042
Nat Biotechnol. 2014 Apr;32(4):381-386
pubmed: 24658644
Nucleic Acids Res. 2016 May 5;44(8):e71
pubmed: 26704973
Nat Genet. 2013 Oct;45(10):1113-20
pubmed: 24071849
Genome Med. 2018 May 23;10(1):37
pubmed: 29792227
Cancer Immunol Res. 2019 Jun;7(6):939-951
pubmed: 31018957
N Engl J Med. 2011 Jun 30;364(26):2517-26
pubmed: 21639810
JCI Insight. 2019 Dec 5;4(23):
pubmed: 31801909
Nature. 2019 Feb;566(7745):496-502
pubmed: 30787437
Clin Cancer Res. 2019 Feb 15;25(4):1233-1238
pubmed: 30054281
J Exp Med. 2013 Aug 26;210(9):1695-710
pubmed: 23897981
Int J Cancer. 2016 May 1;138(9):2263-73
pubmed: 26662627
Neuron. 2019 Jun 19;102(6):1111-1126.e5
pubmed: 31128945
Cancer Res. 2019 Apr 1;79(7):1493-1506
pubmed: 30679180
Proc Natl Acad Sci U S A. 2021 Mar 9;118(10):
pubmed: 33658382
JCI Insight. 2016 Oct 20;1(17):e89829
pubmed: 27777979
Cancer Res. 2009 Dec 1;69(23):9125-32
pubmed: 19903850
Cancer Cell. 2017 Aug 14;32(2):135-154
pubmed: 28810142
Head Neck. 2018 Jun;40(6):1245-1253
pubmed: 29493822
J Immunol. 1999 Oct 15;163(8):4207-12
pubmed: 10510357
Br J Cancer. 2015 Mar 17;112(6):1027-36
pubmed: 25742476
J Immunol. 1995 Aug 15;155(4):1776-83
pubmed: 7543532
Transl Oncol. 2021 Jan;14(1):100930
pubmed: 33186888
Blood. 2003 Jan 1;101(1):202-9
pubmed: 12393538
Nat Immun Cell Growth Regul. 1991;10(5):278-88
pubmed: 1758468
Sci Immunol. 2018 Jan 19;3(19):
pubmed: 29352091
Cancer Immunol Res. 2018 Dec;6(12):1548-1560
pubmed: 30282672
Adv Virol. 2012;2012:702839
pubmed: 22312364
Sci Rep. 2019 Dec 30;9(1):20353
pubmed: 31889137
Trends Genet. 2018 Oct;34(10):790-805
pubmed: 30143323
J Immunol Res. 2019 Nov 4;2019:1919082
pubmed: 31781673
PLoS One. 2019 Jun 26;14(6):e0218674
pubmed: 31242243
Dev Cell. 2020 May 18;53(4):473-491.e9
pubmed: 32386599
BMC Bioinformatics. 2020 Oct 14;21(1):453
pubmed: 33054706

Auteurs

Emily F Davis-Marcisak (EF)

McKusick-Nathans Institute of the Department of Genetic Medicine, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD, USA.

Allison A Fitzgerald (AA)

Department of Oncology, Georgetown Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA.

Michael D Kessler (MD)

Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD, USA.

Ludmila Danilova (L)

Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD, USA.

Elizabeth M Jaffee (EM)

Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD, USA.

Neeha Zaidi (N)

Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD, USA.

Louis M Weiner (LM)

Department of Oncology, Georgetown Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA.

Elana J Fertig (EJ)

Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD, USA. ejfertig@jhmi.edu.
Department of Applied Mathematics and Statistics, Johns Hopkins University Whiting School of Engineering, Baltimore, MD, USA. ejfertig@jhmi.edu.
Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA. ejfertig@jhmi.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH